MYD88 and diffuse large B-cell lymphoma: Conversely, ibrutinib was largely ineffective in patients with germinal-center B-cell-like (GCB)-DLBCL tumors and the larger subset of patients with ABC-DLBCLs that rely on BCR-independent routes of NF-κB activation, such as CARD11 gain-of-function mutations, TNFAIP3/A20 loss-of-function mutations, or MYD88-only mutations [44].